An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia
Information source: University of Colorado, Denver
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Friedreich Ataxia
Intervention: bupropion & Citalopram (Drug); Bupropion & Placebo (Drug); Placebo & Citalopram (Drug); Placebo & Placebo (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: University of Colorado, Denver Official(s) and/or principal investigator(s):
Drew Kern, MD, Principal Investigator, Affiliation: University of Colorado, Denver
Summary
The purpose of this study is to document the clinical effects of bupropion and citalopram in
a single subject with Friedreich Ataxia.
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care
Primary outcome: International Cooperative Ataxia Rating Scale (ICARS)Friedreich Ataxia Rating Scale (FARS)
Secondary outcome: Comparison of FARS and ICARS
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria: N/A -
Exclusion Criteria: N/A
-
Locations and Contacts
Additional Information
Starting date: October 2012
Last updated: October 4, 2013
|
